Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.49 |
| ▸ | HTR1A | P08908 | 10/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14861970 | 0.98 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR1AKCNH2 | |
| SCHEMBL22105815 | 0.80 | SLC6A2 (0.41) | SLC6A2SLC6A4KCNH2 | |
| SCHEMBL22547322 | 0.79 | MCHR1 (0.44) | SLC6A2SLC6A4KCNH2ALOX5 | |
| SCHEMBL21810806 | 0.78 | HTR2C (0.50) | SLC6A2SLC6A4SLC6A3HTR1AKCNH2 | |
| Hydrochloric Acid SCHEMBL21810793 | 0.77 | HTR2C (0.49) | SLC6A2SLC6A4SLC6A3HTR1AKCNH2 | |
| SCHEMBL14873937 | 0.76 | DRD4 (0.38) | SLC6A2SLC6A4KCNH2ALOX5 | |
| SCHEMBL12093082 | 0.76 | SLC6A4 (0.44) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL22547907 | 0.72 | KCNH2 (0.36) | SLC6A2SLC6A4KCNH2ALOX5 | |
| SCHEMBL21525510 | 0.71 | ACSL1 (0.44) | SLC6A2SLC6A4KCNH2 | |
| SCHEMBL12411143 | 0.71 | SLC6A4 (0.36) | SLC6A2SLC6A4SLC6A3HTR1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993477-B2 | Substituted imidazo[1,5-a]pyrazines as PDE9 inhibitors | H. LUNDBECK A/S (DK) | 2018-06-12 | — | — | US | disclosed |
| US-20170173018-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS PDE9 INHIBITORS | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-9643970-B2 | Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors | H. LUNDBECK A/S (DK) | 2017-05-09 | — | — | US | disclosed |
| EP-3121178-A1 | PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE | H. Lundbeck A/S (DK) | 2017-01-25 | — | — | EP | disclosed |
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | PDE9A, PDE5A, PDE12 | SLC6A2 903/4885SLC6A4 1094/4885SLC6A3 504/4885 |
| US-20170173018-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS PDE9 INHIBITORS | PDE9A, PDE12, PDE5A | SLC6A2 766/4885SLC6A4 1190/4885SLC6A3 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.